JAMA Network
What The Study Did: This cohort study examines the risk for ocular adverse events (serous retinal detachment, retinal vascular occlusion and ischemic optic neuropathy) among men using phosphodiesterase type 5 inhibitors (erectile dysfunction drugs that are one of the most prescribed classes of medications in the United States).
Authors: Mahyar Etminan, Pharm.D., M.Sc., of the University of British Columbia in Vancouver, Canada, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaophthalmol.2022.0663)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
